Gilead 1st-qtr profit doubles on strong hepatitis C drug sales

April 30, 2015 8:21 PM

18 0

April 30 (Reuters) - Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates.

Gilead posted first-quarter net income of $4.3 billion, or $2.76 per share, up from $2.2 billion, or $1.33 per share, a year earlier.

Also read: GM to Take $7 Billion Write-Down as a Result of U.S. Tax Overhaul

Read more

To category page